The rotateq market research report is one of a series of new reports that provides rotateq market statistics, including rotateq industry global market size, regional shares, competitors with a rotateq market share, detailed rotateq market segments, market trends and opportunities, and any further data you may need to thrive in the rotateq industry. This rotateq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing prevalence and incidence of infectious diseases, increasing demand for rapid diagnostic solutions, increasing occurrences of infectious diseases, rising health awareness, and increasing prevalence of chronic diseases. Major trends in the forecast period include technological innovations, product approvals, product launches, collaborations and partnerships, and geographic expansions.
The increasing prevalence of rotavirus is expected to fuel the growth of the Rotateq market. Rotavirus is a highly contagious virus that causes severe diarrhea, vomiting, and dehydration, particularly affecting infants and young children. The growing prevalence of rotavirus can be attributed to low vaccination rates and inadequate sanitation, which contribute to its rapid spread, especially in developing areas. Rotateq is an oral vaccine that helps protect infants from rotavirus by stimulating the immune system to produce antibodies that prevent severe dehydration and diarrhea. For example, in August 2024, GOV.UK reported that the cumulative number of rotavirus cases in England up to week 21 of 2024 was 7% higher than the five-season average. Furthermore, rotavirus activity between weeks 18 to 21 of 2024 was 28% higher than the five-season average and 37% higher compared to the previous four-week period. As a result, the increasing prevalence of rotavirus is driving the growth of the Rotateq market.
The rising healthcare expenditure is expected to contribute to the growth of the Rotateq market. Healthcare expenditure includes all spending on medical services, treatments, medications, insurance, and public health programs, funded by individuals, governments, and organizations. The growth in healthcare spending is driven by factors such as aging populations, medical technology advancements, increasing rates of chronic diseases, rising healthcare costs, expanded access to healthcare, and the aftermath of the COVID-19 pandemic. This increase in healthcare expenditure benefits Rotateq by enhancing investments in preventive care, facilitating the wider adoption of vaccines such as Rotateq to combat rotavirus. For instance, the Office for National Statistics reported that UK healthcare spending totaled approximately $354.88 billion (£283 billion) in 2022, a 0.7% increase from the previous year. Therefore, the rising healthcare expenditure is supporting the growth of the Rotateq market.
The growing adoption of personalized medicine is expected to drive the growth of the Rotateq market. Personalized medicine is a healthcare approach that tailors treatments and medical decisions based on an individual’s characteristics, needs, and preferences. This trend is fueled by advancements in genomics, the growing availability of precision diagnostic tools, the increasing demand for targeted therapies, and the need for more effective treatments that are specific to each patient. Rotateq, as a vaccine designed specifically to prevent rotavirus infections, contributes to personalized medicine by addressing the needs of individuals based on risk factors such as age, geographic location, and health conditions, aligning preventive healthcare strategies with tailored medical approaches to improve patient outcomes. For example, in 2022, the Personalized Medicine Coalition reported that 12 new personalized medicines were approved, representing approximately 34% of all newly authorized therapies, a significant increase from the previous year. As a result, the rising adoption of personalized medicine is driving the growth of the Rotateq market.
The key company operating in the rotateq market is Merck & Co. Inc.
North America was the largest region in the rotateq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rotateq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rotateq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
RotaTeq is an oral vaccine designed to protect infants and young children from severe rotavirus infections, which can lead to diarrhea and vomiting. It contains weakened strains of rotavirus to stimulate immunity and is administered in a series of doses starting at 2 months of age to prevent dehydration and the need for hospitalization.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of vaccines related to RotaTeq are Rotarix and Rotavac. Rotarix is a vaccine developed to prevent gastroenteritis caused by rotavirus in infants, protecting against severe diarrhea and dehydration. Key clinical indications for Rotarix include its primary use in infants aged 6 to 32 weeks, prevention of mild to moderate gastroenteritis, and the prevention of severe rotavirus gastroenteritis (RGE). It is distributed through various channels, including hospitals, clinics, and pharmacies.
The rotateq market consists of sales of products including the oral vaccine dropper, oral vaccine suspension bottles, oral dosing syringe, and measuring cups or oral dosing cups. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing prevalence and incidence of infectious diseases, increasing demand for rapid diagnostic solutions, increasing occurrences of infectious diseases, rising health awareness, and increasing prevalence of chronic diseases. Major trends in the forecast period include technological innovations, product approvals, product launches, collaborations and partnerships, and geographic expansions.
The increasing prevalence of rotavirus is expected to fuel the growth of the Rotateq market. Rotavirus is a highly contagious virus that causes severe diarrhea, vomiting, and dehydration, particularly affecting infants and young children. The growing prevalence of rotavirus can be attributed to low vaccination rates and inadequate sanitation, which contribute to its rapid spread, especially in developing areas. Rotateq is an oral vaccine that helps protect infants from rotavirus by stimulating the immune system to produce antibodies that prevent severe dehydration and diarrhea. For example, in August 2024, GOV.UK reported that the cumulative number of rotavirus cases in England up to week 21 of 2024 was 7% higher than the five-season average. Furthermore, rotavirus activity between weeks 18 to 21 of 2024 was 28% higher than the five-season average and 37% higher compared to the previous four-week period. As a result, the increasing prevalence of rotavirus is driving the growth of the Rotateq market.
The rising healthcare expenditure is expected to contribute to the growth of the Rotateq market. Healthcare expenditure includes all spending on medical services, treatments, medications, insurance, and public health programs, funded by individuals, governments, and organizations. The growth in healthcare spending is driven by factors such as aging populations, medical technology advancements, increasing rates of chronic diseases, rising healthcare costs, expanded access to healthcare, and the aftermath of the COVID-19 pandemic. This increase in healthcare expenditure benefits Rotateq by enhancing investments in preventive care, facilitating the wider adoption of vaccines such as Rotateq to combat rotavirus. For instance, the Office for National Statistics reported that UK healthcare spending totaled approximately $354.88 billion (£283 billion) in 2022, a 0.7% increase from the previous year. Therefore, the rising healthcare expenditure is supporting the growth of the Rotateq market.
The growing adoption of personalized medicine is expected to drive the growth of the Rotateq market. Personalized medicine is a healthcare approach that tailors treatments and medical decisions based on an individual’s characteristics, needs, and preferences. This trend is fueled by advancements in genomics, the growing availability of precision diagnostic tools, the increasing demand for targeted therapies, and the need for more effective treatments that are specific to each patient. Rotateq, as a vaccine designed specifically to prevent rotavirus infections, contributes to personalized medicine by addressing the needs of individuals based on risk factors such as age, geographic location, and health conditions, aligning preventive healthcare strategies with tailored medical approaches to improve patient outcomes. For example, in 2022, the Personalized Medicine Coalition reported that 12 new personalized medicines were approved, representing approximately 34% of all newly authorized therapies, a significant increase from the previous year. As a result, the rising adoption of personalized medicine is driving the growth of the Rotateq market.
The key company operating in the rotateq market is Merck & Co. Inc.
North America was the largest region in the rotateq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rotateq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rotateq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
RotaTeq is an oral vaccine designed to protect infants and young children from severe rotavirus infections, which can lead to diarrhea and vomiting. It contains weakened strains of rotavirus to stimulate immunity and is administered in a series of doses starting at 2 months of age to prevent dehydration and the need for hospitalization.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of vaccines related to RotaTeq are Rotarix and Rotavac. Rotarix is a vaccine developed to prevent gastroenteritis caused by rotavirus in infants, protecting against severe diarrhea and dehydration. Key clinical indications for Rotarix include its primary use in infants aged 6 to 32 weeks, prevention of mild to moderate gastroenteritis, and the prevention of severe rotavirus gastroenteritis (RGE). It is distributed through various channels, including hospitals, clinics, and pharmacies.
The rotateq market consists of sales of products including the oral vaccine dropper, oral vaccine suspension bottles, oral dosing syringe, and measuring cups or oral dosing cups. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rotateq Market Characteristics4. Rotateq Market Trends And Strategies5. Rotateq Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Rotateq Pricing Analysis & Forecasts30. Global Rotateq Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Rotateq Market32. Recent Developments In The Rotateq Market
3. Rotateq Market Biologic Drug Characteristics
6. Global Rotateq Growth Analysis And Strategic Analysis Framework
8. Rotateq Market Segmentation
9. Global Rotateq Epidemiology Of Clinical Indications
10. Rotateq Market Regional And Country Analysis
11. Asia-Pacific Rotateq Market
12. China Rotateq Market
13. India Rotateq Market
14. Japan Rotateq Market
15. Australia Rotateq Market
16. South Korea Rotateq Market
17. Western Europe Rotateq Market
18. UK Rotateq Market
19. Germany Rotateq Market
20. France Rotateq Market
21. Eastern Europe Rotateq Market
22. North America Rotateq Market
23. USA Rotateq Market
24. Canada Rotateq Market
25. South America Rotateq Market
26. Middle East Rotateq Market
27. Africa Rotateq Market
28. Rotateq Market Competitive Landscape And Company Profiles
29. Global Rotateq Market Pipeline Analysis
33. Rotateq Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Rotateq Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rotateq market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rotateq ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rotateq market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Rotarix; Rotavac2) By Clinical Indication: Primary Indication; Infants (6 To 32 Weeks); Mild To Moderate Gastroenteritis; Prevention Of Severe Rotavirus Gastroenteritis (RGE)
3) By Distribution Channel: Hospitals; Clinics; Pharmacies
Key Companies Profiled: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
